OncoDxRx is mobilizing its resources to counter these risks. Systems such as PGA (Patient-derived Gene expression-informed Anticancer drug efficacy) and OncoMRD (Monitoring Residual Disease), as well as innovations in liquid biopsy transcriptomics, illustrate OncoDxRx's efforts to respond rapidly and cost-effectively to this threat. These technologies were successfully put into practice, underlining their effectiveness in complex clinical environments.

Cancer represents an asymmetric threat capable of bypassing traditional defenses. Its first-line therapeutic strategy comes with the high price of targeted therapy or immunotherapy. These burdens require cost-effective, rapid and automated diagnostic solutions, and reflect the urgent need to develop effective tools in the face of these threats.

According to OncoDxRx, the rapid integration of patient gene expression data and its transmission to analytical system must be automated to guarantee more real-time responses. This approach reduces operational costs while increasing the accuracy and speed of interventions. PGA and OncoMRD illustrate this trend.

By investing massively in these technologies, OncoDxRx is not only responding to an immediate threat, but also anticipating future cancer theranostics in which "circulating cell-free transcriptomics" will play a central role.

Highly personalized and based on exclusive and disruptive technology, PGA and OncoMRD significantly increase our ability to identify and control clinical situations, as well as facilitating decision-making through actionable information obtained from different layers of biomarkers.

These new capabilities enable OncoDxRx to maintain a high level of knowhow and trade secret with its own technologies. In this way, OncoDxRx ensures its control over liquid biopsy transcriptomics, personalized gene signature, gene-drug mapping, residual disease monitoring and contributes to the maintenance of an autonomous situational awareness capability. A major asset in an increasingly complex precision diagnostics context.

"With PGA and OncoMRD, we are preparing for the next generation, that of drug efficacy/response prediction and post-therapy disease followup in patients unresponsive to precision medicine," OncoDxRx stated.

The launch of PGA and OncoMRD aims, in particular, to increase personalized diagnostics to progressively meet the needs of precision theranostics, thanks to new high-speed, low-latency sample-to-result testing workflow that can be quickly deployed in most labs.

The resilience of the technologies will also be strengthened by the development of rapid reconfiguration mechanisms to adapt to the available instruments in different clinical and operational scenarios. In the face of growing cyber threats, the in silico data analytics will also rely on enhanced cybersecurity to preserve the integrity and continuity of operations.